Candriam S.C.A. Curis Inc Transaction History

Candriam S.C.A.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 03, 2022	SELL	$0.71 - $2.43 $138,450 - $473,850	-195,000 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$2.31 - $5.13 $8.92 Million - $19.8 Million	-3,859,920 Reduced 95.19%	195,000 $464,000
Q4 2021 Feb 10, 2022	BUY	$4.45 - $8.09 $4.59 Million - $8.35 Million	1,031,914 Added 34.14%	4,054,920 $19.3 Million
Q3 2021 Nov 09, 2021	BUY	$6.94 - $8.85 $3.77 Million - $4.8 Million	542,843 Added 21.89%	3,023,006 $24.3 Million
Q2 2021 Jul 20, 2021	BUY	$7.45 - $16.27 $18.5 Million - $40.4 Million	2,480,102 Added 4065741.0%	2,480,163 $20 Million
Q1 2021 Apr 29, 2021	BUY	$8.78 - $12.8 $535 - $780	61 New	61 $1,000
Q4 2018 Feb 14, 2019	SELL	$0.62 - $2.25 $99,200 - $360,000	-160,000 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$1.73 - $3.35 $276,800 - $536,000	160,000 New	160,000 $277,000

Ticker CRIS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 91,814,704
Market Cap $393M
Description
Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myel...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.